How many drugs treat Bronchitis?

Drug Landscape tracks 10 marketed treatments for Bronchitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Bronchitis?

Most recent: Bupivacaine Hydrochloride And Epinephrine — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bronchitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bronchitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bronchitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Cysteine Hydrochloride	CYSTEINE	Exela Pharma	Vitamin C [EPC]	Cystine/glutamate transporter	1986-01-01
Tornalate	BITOLTEROL	Sanofi	bitolterol	Beta-2 adrenergic receptor	1984-01-01
Ciclacillin	CYCLACILLIN	Pfizer	cyclacillin		1979-01-01
Minocycline Hydrochloride	MINOCYCLINE	Rempex	Tetracycline-class Drug		1971-01-01
Vibramycin	doxycycline	Generic (originally Pfizer)	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Abelcet	AMPHOTERICIN B	Astellas Pharma	Lipid-based Polyene Antifungal [EPC]		1964-01-01
Acetadote	Acetylcysteine	Bristol-Myers Squibb	Antidote	Glutathione levels; reactive metabolite of acetaminophen	1963-01-01
Demethylchlortetracycline	DEMECLOCYCLINE	Pfizer	Tetracycline-class Antimicrobial	Estrogen receptor beta	1960-01-01
Norepinephrine Bitartrate In 5% Dextrose	NOREPINEPHRINE	Pfizer	Catecholamine	alpha-adrenergic receptors, beta-adrenergic receptors	1950-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-30 — Bupivacaine Hydrochloride And Epinephrine · FDA · approved · US
2026-03-26 — Norepinephrine Bitartrate In 5% Dextrose · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 11 drugs in Bronchitis
Pfizer · 3 drugs in Bronchitis
Pfizer Inc. · 2 drugs in Bronchitis
Bristol-Myers Squibb · 1 drug in Bronchitis
Bulovka Hospital · 1 drug in Bronchitis
Exela Pharma · 1 drug in Bronchitis
Generic (originally Pfizer) · 1 drug in Bronchitis
Johnson And Johnson · 1 drug in Bronchitis
Louisiana State University Health Sciences Center Shreveport · 1 drug in Bronchitis
Astellas Pharma · 1 drug in Bronchitis
Assistance Publique - Hôpitaux de Paris · 1 drug in Bronchitis
Rempex · 1 drug in Bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bronchitis:

Cite this brief

Drug Landscape (2026). Bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bronchitis. Accessed 2026-06-10.

Bronchitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing